title: Loratidine improves ischemic parameters of exercise stress test in patients with acute myocardial infarction.
abstract: BACKGROUND
  This study sought to determine whether adding an anti-histaminic medication, loratidine, to anti-ischemic treatment would ameliorate or improve ischemic parameters induced by exercise stress test in patients who suffered an acute myocardial infarction.
  
  
  METHODS
  Twenty stable patients with acute inferior myocardial infarction who had a positive EST were randomly allocated into 2 groups, A and B. Patients in group A and B received a 10 mg loratidine tablet added daily to their anti-ischemic regimen for 7 days during the second and third week post-event, respectively. At the end of each period they underwent an exercise stress test (EST). Exercise parameters in each group were then compared before and after loratidine therapy.
  
  
  RESULTS
  Both groups showed improvements in exercise parameters after loratidine therapy compared to basal EST results. ST(max) ( group A: 1.9 +/- 0.74 vs 0.9 +/- 1.29 mm, P = .046; group B: 2.5 +/- 0.71 vs 1.4 +/- 1.17 mm, P = .041), ST(lead) ( group A: 3.4 +/- 1.08 vs 1.5 +/- 2.12, P = .027; group B: 4.6 +/- 1.71 vs 2.22 +/- 2.25, P = .011), ST(total) ( group A: 4.7 +/- 2.18 vs 2.1 +/- 3.11 mm, P = .024; group B: 7.9 +/- 2.92 vs 3.33 +/- 3.81 mm, P = .005).
  
  
  CONCLUSIONS
  Our study revealed that loratidine, a histamine-1 receptor blocker, improves ischemic parameters of EST when given as additive therapy to a routine anti-ischemic regimen during the sub-acute phase of myocardial infarction.
authors.affiliation: Department of Cardiology, School of Medicine, Trakya University, Edirne, Turkey. okanerdogan@yahoo.com <okanerdogan@yahoo.com>
authors.forename: Okan
authors.initials: O
authors.lastname: Erdogan
authors.forename: Armagan
authors.initials: A
authors.lastname: Altun
authors.forename: Sabri
authors.initials: S
authors.lastname: Gazi
authors.forename: Gultac
authors.initials: G
authors.lastname: Ozbay
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000517:prevention & control*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D039563:Histamine H1 Antagonists, Non-Sedating; D017336:Loratadine